2015 News Releases

Pacira Pharmaceuticals, Inc. to Present at the 34th Annual J.P. Morgan Healthcare Conference
12/28/15
Pacira Pharmaceuticals Announces Favorable Resolution With U.S. Food and Drug Administration, Which Reaffirms the Broad Indication for EXPAREL®
12/15/15
Pacira Pharmaceuticals, Inc. to Present at the 27th Annual Piper Jaffray Healthcare Conference
11/24/15
New Survey Sheds Light on Prescription Drug Use Among Women After Surgery in the United States
11/17/15
Pacira Pharmaceuticals, Inc. to Present at the Jefferies Autumn 2015 Global Healthcare Conference
11/11/15
New Study Finds Decreased Opioid Use, Hospital Stay and Readmission Rates With EXPAREL Following Knee Replacement Surgery
11/06/15
Pacira Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial Results
10/27/15
Pacira Pharmaceuticals Announces the Promotion of James S. Scibetta to President
10/20/15
Pacira Pharmaceuticals Announces Timing for Third Quarter 2015 Financial Results Webcast and Conference Call
10/13/15
Pacira Pharmaceuticals Seeks Court Injunction to Defend its Rights to Share Information about EXPAREL® Consistent with its FDA-Approved Indication
09/08/15
Pacira Pharmaceuticals Appoints James B. Jones, MD, PharmD, as Senior Vice President and Chief Medical Officer
08/19/15
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in August
08/03/15
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2015 Financial Results
07/30/15
Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results for Controlling Postsurgical Pain in Dogs
07/15/15
Pacira Pharmaceuticals Announces Timing for Second Quarter 2015 Financial Results Webcast and Conference Call
07/14/15
Pacira Pharmaceuticals Appoints Scott Braunstein, MD, to Oversee Strategy and Corporate Development
07/14/15
Pacira Pharmaceuticals Announces Completion of End-of-Review Process with FDA Regarding EXPAREL sNDA for Nerve Block
05/28/15
Pacira Pharmaceuticals, Inc. to Present at Investor Conferences in June
05/20/15
Pacira Announces New Data Supporting Clinical and Pharmacoeconomic Utility of EXPAREL in Patients Undergoing Various Surgical Procedures
05/19/15
Pacira Pharmaceuticals, Inc. to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
05/07/15
Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues of $56.0 Million and First Quarter 2015 Financial Results
04/30/15
Pacira Receives Subpoena from the U.S. Department of Justice
04/16/15
Pacira Pharmaceuticals Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call
04/13/15
Pacira Announces New Data on Health Economic Benefits of EXPAREL for Postsurgical Pain Control Following Total Knee Replacement Surgery
04/10/15
Pacira Announces Data Reinforcing Benefits of EXPAREL® for Postsurgical Pain Control Following Total Hip and Knee Replacement Surgery
03/26/15
New Data Demonstrate Reduced Opioid Requirements Following Use of EXPAREL in Hysterectomy and Mastectomy Procedures
03/23/15
Pacira Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
03/04/15
Pacira Receives Complete Response Letter from FDA for sNDA Seeking Approval of EXPAREL® Use in Nerve Block to Provide Postsurgical Analgesia
03/02/15
Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results
02/24/15
Pacira Pharmaceuticals, Inc. Announces Resolution of Warning Letter with FDA’s Office of Prescription Drug Promotion
02/11/15
Pacira Pharmaceuticals Announces Timing for 2014 Financial Results Webcast and Conference Call
02/10/15
Pacira Pharmaceuticals, Inc. to Host Analyst & Investor Day on Jan. 22 in New York
01/08/15
Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue of $61.8 Million and Estimated Full-Year Total Revenue of $197.7 Million
01/08/15